What is Antimicrobial Resistance and Why Does It Matter for UTI Treatment?

Urinary tract infections (UTIs) are one of the most commonly treated bacterial infections in the world, and antibiotics are the standard approach for clearing them. But a growing problem is making UTI treatment harder for everyone: antimicrobial resistance [1]. Understanding what resistance is, how it develops, and why it matters for your treatment can help you make more informed decisions about your care.

What is Antimicrobial Resistance?

Antimicrobial resistance occurs when bacteria or fungi evolve in ways that allow them to survive exposure to antibiotics (or antifungals) that would normally kill them or stop them from multiplying. When this happens, the medication no longer works as intended, and an infection that might once have cleared up in a few days can become much harder to treat.

Resistance can develop over time as bacteria reproduce and occasionally mutate – producing changes in existing genes, creating new genes, or sharing genes with one another to ensure their survival. However, the overuse and misuse of antibiotics dramatically accelerates this process. When antibiotics are over or misused, including taking them when not needed, not completing a full course, or using antibiotics prescribed for a different infection, the bacteria that survive are more likely to be resistant.

Why Are UTIs Particularly Affected?

UTIs are among the most common reasons antibiotics are prescribed globally. Because of this volume, UTI-causing bacteria like Escherichia coli (E. coli) — responsible for the vast majority of uncomplicated UTIs — have had many opportunities to develop and spread resistance. This is compounded by a common clinical practice called “empiric treatment”, in which a provider prescribes an antibiotic before laboratory results confirm which bacteria is causing the infection, or which antibiotics it is sensitive to.

Empiric treatment can be appropriate and necessary, particularly for patients in discomfort who cannot wait several days for urine culture results. However, when the prescribed antibiotic turns out to be one that the bacteria is resistant to, the infection may not clear, and patients may experience worsening symptoms, reinfection, or complications.

How Does Antimicrobial Resistance Make UTIs Harder to Treat?

When the pathogen causing your UTI is resistant to the antimicrobial you were prescribed, there are several consequences. The infection may not clear at all. Your symptoms may improve temporarily but then return once you finish the treatment course, a pattern commonly seen in recurrent and complicated UTIs. In more serious cases, the infection can ascend to the kidneys or enter the bloodstream, becoming a medical emergency.

For patients who experience recurrent UTIs, the risk is compounded with each treatment course [2]. Repeated or inappropriate antimicrobial use creates selection pressure — an environment where resistant pathogens are more likely to survive and dominate. Over time, some patients may find that multiple drugs no longer work against their particular infection, limiting their treatment options significantly.

The Problem with Empiric Treatment

Most UTIs are initially treated empirically, meaning antibiotics are prescribed based on clinical judgment and local resistance patterns before test results are available [3]. This approach makes sense when speed matters — no one wants to wait days in pain for a definitive answer. But it also means that a meaningful proportion of patients receive an antibiotic that will not work against their specific infection.

Without knowing exactly which bacteria is causing the infection and which antibiotics it is resistant to, treatment becomes an educated guess. For straightforward, first-time UTIs in otherwise healthy individuals, this guess is often correct. For patients with recurrent, complicated, or culture-negative UTIs, the stakes are much higher and the guess is much harder to make correctly.

Antimicrobial Resistance: An Imperfect Science

Antimicrobial resistance is difficult to measure accurately. The current standard of care for determining antimicrobial resistance is through the use of a laboratory technique called antimicrobial susceptibility testing (AST), which is performed on isolated bacterial colonies or fungi grown from urine samples. Through this, the pathogen is grown on petri dishes with varying concentrations of different drugs, which when read together provide the lab with a value called the minimum inhibitory concentration (MIC). The MIC is then used to determine which treatment the pathogen(s) detected may respond to best.

However, there are limitations to this method. Because it is performed under laboratory conditions the bacteria may not necessarily behave the same way it would in the body. In the body, the pathogen is under pressure from the person's immune system, unique microbiome, and other factors that can alter the expression of resistance genes. It becomes more challenging when considering the patient's own metabolism of the drug, and whether a high enough concentration of it is able to reach the site of the infection.

Molecular diagnostics, or DNA-based tests, are enabling faster and more accurate antimicrobial resistance prediction through the detection of resistance markers, or specific genes that are known to play a role in resistance, without needing separate AST following urine culture. Although resistance genes may be found, it is unknown how the medication will affect the pathogen in the body. Ultimately, your provider will make a recommendation based on the available diagnostic results, their understanding of AMR trends in the community or hospital setting, and your own medical history.

What Are Antimicrobial Resistance Markers?

Antimicrobial resistance markers are sequences of DNA within pathogens that encode resistance mechanisms — essentially, the machinery that allows it to survive in the presence of a drug designed to eliminate it. Identifying these markers is critically important for precision treatment. Knowing that a particular strain of E. coli carries a specific resistance gene allows a clinician to avoid prescribing an antibiotic that will not work, and instead choose one that the bacteria is still sensitive to. This kind of targeted treatment is safer for the patient, more effective at clearing the infection, and contributes less to the broader problem of resistance in the community.

How Molecular Diagnostic Testing Addresses Antimicrobial Resistance

Standard urine culture can identify the bacteria causing a UTI and test its sensitivity to common antibiotics through AST. However, this process takes several days, and urine culture itself misses a meaningful proportion of infections — particularly in patients with recurrent or complicated UTIs, or those who have recently taken antibiotics.

PCR

The most common molecular diagnostic testing used a technique called polymerase-chain reaction (PCR). Many may be familiar with this term as it was the gold standard test for SARS-CoV-2, the virus that caused the COVID-19 pandemic. PCR is a targeted technique – meaning it looks for known genes of specific microbes. While useful for identifying resistance markers with high accuracy, it is inherently limited to the resistance markers the test was designed to detect. Moreover, it may find resistance markers from microbes that are not actually causing the infection, which may unnecessarily exclude treatment options.

Next-generation sequencing

Another type of molecular diagnostic testing is called next-generation sequencing (NGS). This type of testing is at the cutting edge of infectious disease diagnostics. Rather than attempting to grow pathogens on a petri dish, these tests detect and analyze the DNA present in a urine sample directly and compare what was found to large pathogen databases that may also contain antimicrobial resistance information.

Some NGS tests will only look for a fraction of the pathogen DNA, while others will look at all of the pathogen DNA. In the former case, separate PCR testing is necessary to identify resistance genes. In the latter case, when a resistance gene is found, you are able to predict how likely it is that the detected pathogen will actually be resistant to various drugs. Biotia's test for recurrent, complicated, and culture-negative UTIs, the BIOTIA-ID Urine Test, uses clinical metagenomics, an advanced form of next-generation sequencing that enables us to predict antimicrobial resistance.

When a pathogen is detected by the BIOTIA-ID Urine Test it is simultaneously screened for 16 antimicrobial resistance markers. No separate PCR test is required. These 16 resistance markers were chosen because they are highly correlated with resistance, meaning that when a pathogen has one or multiple of these genes, it is more likely than not that it will be resistant to the drug. This allows your doctor to make both a more informed and more confident treatment decision from the start — helping to avoid unnecessary or inappropriate antimicrobial use while ensuring you receive a treatment that is more likely to work.

What Can Patients Do?

Antimicrobial stewardship — the responsible use of antibiotics and antifungal medications — is something both patients and providers can practice. Here are some steps that can help.

• Always complete your full treatment course, even if you feel better before it is finished. Stopping early can leave behind partially resistant bacteria or fungi.
• Never take antibiotics or antifungals prescribed for someone else or for a different infection. Different drugs target different pathogens, and using the wrong one can contribute to resistance without treating your infection.
• Let your doctor know about any antibiotic or antifungal medications you have taken recently, as this information is relevant to both the likelihood of resistance and the interpretation of test results.
• If you experience UTI symptoms that do not improve or return quickly after treatment, follow up with your doctor rather than waiting.
• If you have had multiple UTIs or prior treatment failures, ask your provider about diagnostic testing that includes resistance marker detection, such as the BIOTIA-ID Urine Test. When possible, get tested for resistance prior to starting medication.

The Bottom Line

Antimicrobial resistance is a genuine and growing challenge for UTI treatment, particularly for patients who experience recurrent or complicated infections. The more targeted and accurate the diagnostic information available to your clinician, the better equipped they are to select a treatment that will actually work. Advanced testing that can detect both pathogens and resistance markers — like next-generation sequencing-based tests — is an important part of addressing this challenge and protecting both individual patients and public health.